Genetic Testing for Hereditary Cancers Can Help Reduce the Risk of Cancer
By detecting cancer early, your patient will have access to preventative measures and proactive treatment – leading to an overall better prognosis.
Genetic Diagnosis of Hereditary Cancer
Testing for hereditary cancers can detect specific, heritable, disease-related gene mutations that may increase the risk of certain cancers allowing an in-depth cancer risk assessment for each patient.
The critical goal is to detect cancer early and to give you the opportunity to maximize health outcomes for your patients. Patient-tailored screening programs, preventive measures and proactive treatment are possible for patients of a high-risk group. Early diagnosis can mean a better overall prognosis through a choice of surgical and non-surgical treatment options.
Hereditary Cancer Feature List
Excellent analysis using the most advanced NGS technology
Includes detection of Copy Number Variants (CNVs)
Affordable prices and shortest turnaround times
Highest level of quality/accuracy
CAP and CLIA and ISO certification and accreditation
Breast and Ovarian Cancer
Providing critical information for affected and non-affected individuals
Comprehensive Cancer Panel
CentoCancer® – CENTOGENE's cancer-risk-related panel, for all patients with a positive family history of cancer
Breast and Ovarian Cancer
Breast cancer is one of the most common cancers in the world affecting ~12.5% of women during their lifetime. 5–10% of these patients have a hereditary form.
Mutations in the BRCA1 and BRCA2 genes are the most common hereditary cause. However, other genes such as ATM, BRIP1, CHEK2, PALB2, RAD51, etc. have also been associated with increased risk.
| Gene test | BRCA1/BRCA2 | CentoBreast® |
|---|---|---|
| Gene name | BRCA1, BRCA2 | ABRAXAS1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, FANCC, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS1, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SMARCA4, STK11, TP53, XRCC2 |
| Diseases covered | Breast cancer | Breast cancer, ovarian cancer |
| Turnaround time | 15 business days | 15 business days |
| How to order | Order a test | Order a test |
Comprehensive Cancer Panel
CentoCancer® is a specific and sensitive panel with all known highly penetrant cancer genes. Each gene has been carefully selected based on its risk potential in the development of one of the following cancers: breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer.
| Gene test | CentoCancer® |
|---|---|
| Genes name | ABRAXAS1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, DIS3L2, EPCAM, FANCC, FH, FLCN, GALNT12, HNF1B, HOXB13, KIT, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS1, PMS2, POLD1, POLE, POT1, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL, RET, RNF43, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TGFBR2, TP53, TSC1, TSC2, VHL, WT1, XRCC2, XRCC3 |
| Diseases covered | Breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer |
| Turnaround time | 15 business days |
| How to order | Order a test |
Resources
Useful Links
Downloads
Hereditary Cancer Panels – Product Sheet
Genetic testing for an improved prognosis
Scientific Publications
Ultra-Rare Immune Disorder Uncovered
Homeostasis of the immune system is key for human health. Recently, CENTOGENE carried out an analysis of clinical and genetic data from the CENTOGENE Biodatabank, which enabled the identification of […]
Related Webinars
MOx – Advancing Rare Disease Patient Care With Multiomic Solutions
Watch the on-demand webinar now to gain insights into our multiomics revolution – a multidimensional approach looking at each patient from different angles to combine deep knowledge and insights for […]
Rewrite the Future of Rare Diseases With Multiomics
Our speakers, Maximilian Schmid M.D., Chief Commercial Officer – Diagnostics, and Prof. Peter Bauer M.D., Chief Genomic Officer, will highlight the power of multiomics in establishing a complete […]
NEW CentoXome® – Turning Our Expertise Into Your Advantage
Dr. Aida Bertoli-Avella and Dr. Jorge Pinto-Pasto provide you with an exclusive look into our enhanced Whole Exome Sequencing (WES) solution – NEW CentoXome.
Get in Touch With Our Customer Support
Our consultation service is available in several languages.
+49 (0) 381 80 113 - 416
Mon. – Fri. 7 a.m. – 6:30 p.m. CET
Sat. 8 a.m. – 12 p.m. CET